Clinical trials: No Disease
Adenocarcinoma (NOS), Anal Cancer
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease…
- Conditions
- Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- DP-04 (NCT07124000)
- Testing
- Trastuzumab deruxtecan
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
PTSD
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) - a sublingual formulation of cyclobenzaprine.
- Trial name
- RECOVERY (NCT03841773)
- Testing
- TNX-102 SL
- Where
- 30 sites in United States
- Volunteers
- 192 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Heart Failure, Cardiac Resynchronization Therapy
Safety and Performance Aspects of CRT-DX System in Patients With Sinus Rhythm
The conventional CRT-D system consists of 3 leads in patients with Heart Failure (HF). A part of HF patients have non-impaired sinus node function and will not be stimulated in the right atrium.
- Trial name
- BIO|REDUCE (NCT03839121)
- Testing
- Cardiac Resynchronization Therapy (CRT)
- Where
- 21 sites in Austria, Czechia and 2 more
- Volunteers
- 113 people
- Sponsor
- Biotronik SE & Co. KG
Chronic Hepatitis C Infection
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of response-guided duration of therapy with GS-9190 and GS-9256 in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
- Trial name
- NCT01225380
- Testing
- GS-9190, GS-9256, Pegasys®
- Where
- 114 sites in United States, Austria and 9 more
- Volunteers
- 324 people
- Sponsor
- Gilead Sciences
Normal Healthy Subjects With no Known Ocular Diseases
Retinal Fundus Camera Evaluation
Establish a normal baseline setting configuration for image capture using the Topcon TRC-NW400 non-mydriatic retinal camera.
- Trial name
- NCT02293174
- Testing
- Topcon TRC-NW400, TRC-NW8, TRC-NW400
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Topcon Medical Systems, Inc.
Malignant Melanoma
A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)
This is a study to evaluate the safety and tolerability of peginterferon alfa-2b (PegIFN alfa-2b) as adjuvant treatment in Japanese participants with malignant melanoma after definitive surgical resection including complete…
- Trial name
- NCT01636960
- Testing
- PegIFN alfa-2b
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Vascular Diseases
DENEX Renal Denervation in Patients With Hypertension on no Antihypertensive Medications
The objective of this study is to evaluate the safety and effectiveness of renal denervation using DENEX System in patients with hypertension without antihypertensive medication, compared with the sham group.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT04535050
- Testing
- Renal denervation, Renal angiography
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Kalos Medical
Thrombotic Thrombocytopenic Purpura (TTP)
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2)…
- Trial name
- NCT05714969
- Testing
- TAK-755
- Where
- 22 sites in United States, Austria and 4 more
- Volunteers
- 29 people
- Sponsor
- Takeda
Non-Small Cell Lung Cancer, Colorectal Cancer
Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
An interventional, prospective clinical performance study protocol, for the testing of DNA extracted from tumor tissue biopsy samples, using the therascreen® KRAS RGQ PCR Kit, from patients with Non-Small Cell Lung Cancer and…
- Trial name
- NCT05348187
- Testing
- therascreen® KRAS RGQ PCR Kit
- Where
- United Kingdom
- Volunteers
- 309 people
- Sponsor
- QIAGEN Gaithersburg, Inc
No Disease
Efficacy of Polyphenols From Milk and Dark Chocolate
Dark chocolate is one of the richest sources of polyphenols though it has been hypothesised that the bioavailability and therefore probably the bioefficacy of epicatechin from milk chocolate was reduced compared to dark.
- Trial name
- NCT00513344
- Testing
- Dark Chocolate, Milk Chocolate, Control (polyphenol-free) "Chocolate"
- Where
- Switzerland
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Coronary Disease, Coronary Heart Disease
Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease
Treatment for no-option heart patients with coronary artery disease. Procedure includes the injection into the heart of a protein growth factor, administered by the Biological Delivery Systems MyoStar injection and mapping…
- Conditions
- Coronary Disease, Coronary Heart Disease, Myocardial Ischemia, Coronary Arteriosclerosis
- Trial name
- NCT00117936
- Testing
- Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose
- Volunteers
- 150 people
- Sponsor
- Venturis Therapeutics, Inc.
Breast Cancer, Early Breast Cancer
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease…
- Trial name
- CAMBRIA-2 (NCT05952557)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 661 sites in United States, Argentina and 42 more
- Volunteers
- 5,511 people
- Sponsor
- AstraZeneca
Anemia
The Duration Study
The purpose of this study is to compare the efficacy of epoetin alfa (PROCRIT®) administered subcutaneously (sc) once every week (qw) vs. no epoetin alfa (PROCRIT®) treatment in patients with cancer who are anemic.
- Trial name
- NCT00210730
- Testing
- epoetin alfa
- Volunteers
- 2 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Liver Cancer
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.
- Trial name
- NCT02013830
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda]
- Where
- 7 sites in Australia, Hong Kong and 2 more
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Asthma
Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)
This study is designed to show that pharmacotherapy guided by eNO and clinical standard of care produces a superior outcome to trial-based therapy guided by clinical standard of care alone.
- Trial name
- Outcomes (NCT00739219)
- Testing
- Apieron Insight eNO monitor
- Where
- 12 sites in United States
- Volunteers
- 260 people
- Sponsor
- Apieron
Corona Virus Infection, COVID-19
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)
The purpose of this open label, randomized, study is to obtain information on the safety and efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.
- Conditions
- Corona Virus Infection, COVID-19, SARS-CoV 2, Nitric Oxide
- Trial name
- NCT04397692
- Testing
- Nitric Oxide delivered via LungFit™ system
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Beyond Air Inc.
Bronchiolitis
Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis
Prospective, Double Blind, Randomized Single-Center, Evaluation of Safety and Tolerability of Nitric Oxide Given Intermittently via Inhalation to Subjects with Bronchiolitis-Phase IIa Bronchiolitis is defined as an infection of…
- Trial name
- NCT01768884
- Testing
- Nitric Oxide
- Where
- Israel
- Volunteers
- 43 people
- Sponsor
- Beyond Air Inc.
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
The aim of this study is to evaluate the safety and immunogenicity of Fluzone® Quadrivalent vaccine in participants aged 6 months to < 9 years at enrollment, divided into 2 age strata (6 months to < 36 months and 3 years to < 9…
- Trial name
- NCT01946425
- Testing
- Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
General Population (no Specific Condition or Disease)
Effect of Storytelling on Questionnaire Completion and Quality of Collected Data in an E-Cohort
This study is a randomized controlled trial, nested in the SKETHIS e-cohort, aiming to evaluate whether adding a modest, narrative-driven, strorytelling introduction to a Patient-Reported Outcome questionnaire increases…
- Trial name
- PEGASYS (NCT07475338)
- Testing
- Storytelling questionnaire
- Where
- France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- SKEZI
Infertility
Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)
The purpose of this follow-up study is to collect the outcome and safety of FTET cycles after the embryos are cryopreserved in P06029 (NCT01144416).
- Trial name
- NCT01146418
- Testing
- Corifollitropin alfa, recFSH (follitropin beta)
- Volunteers
- 307 people
- Sponsor
- Organon and Co